

SpringWorks Therapeutics, Inc.

NDC	DRUG PROD DESC	INTRODUCED TO MARKET DATE
82448-0050-18	OGSIVEO (Nirogacestat) 50mg tablets, 180-ct bottle	12/4/2023

WAC AT INTRODUCTION

\$29,000

MARKETING PRICING PLAN

Desmoid tumors are a rare, devastating disease, with a potentially significant burden of illness on patients. OGSIVEO™ (nirogacestat) is the first and only FDA-approved treatment indicated for adult patients with progressing desmoid tumors who require systemic treatment. Patients afflicted with desmoid tumors often have significant unmet need. OGSIVEO will be marketed to appropriate healthcare professionals in both community oncology and sarcoma centers of excellence in the U.S., as well as adult patients in the U.S. with desmoid tumors. General marketing efforts will be focused on highlighting the approved indication, efficacy, safety and value that OGSIVEO may deliver to appropriate patients in need. Specific marketing plans used to launch the drug in the U.S. include, without limitation, use of print and digital media, patient and HCP websites, opt in email communications, media advertisements to both healthcare providers and patients on platforms such as social media and other web-based mediums, professional detailing to healthcare providers, and conference events, seminars and speaker programs. Patient support programs will also be offered to facilitate access to OGSIVEO for eligible patients who have been prescribed OGSIVEO, but these programs are not considered marketing or promotional activities.

With respect to its pricing plans for OGSIVEO in the U.S., SpringWorks conducted extensive qualitative and quantitative market research and analysis of several factors, including unmet medical need, disease severity, and patient burden of illness in this orphan population. Additionally, SpringWorks assessed current market pricing for comparable orphan rare disease and oncology drugs, which included broad-based physician, payer and population health decision maker feedback. Additional financial and non-financial factors were considered in establishing the wholesale acquisition cost for OGSIVEO, including: the unique clinical value that OGSIVEO offers as the first and only FDA-approved gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment; the safety and efficacy profile of the drug; patient access considerations, including the development and implementation of the SpringWorks CareConnections patient support program to support U.S. patients on their treatment journey with OGSIVEO; preclinical and ongoing clinical trials for the drug; anticipated discounts and other fees to be negotiated with supply chain partners, including wholesalers, specialty pharmacies, and group purchasing organizations; anticipated discounts, rebates and fees to various government programs; manufacturing and marketing costs; and past and ongoing investments in R&D (including resources, infrastructure and organization) to both support and build on the existing portfolio and develop new and innovative therapies for other rare indications.

SpringWorks does not currently market or sell OGSIVEO outside the U.S.

MARKETING PRICING NONPUBLIC	ESTIMATED PATIENTS	BREAKTHROUGH THERAPY INDICATOR
No	1311	Yes

PRIORITY REVIEW INDICATOR	ACQUISITION DATE	ACQUISITION PRICE
Yes	8/18/2017	\$ 232,500,000.00

ACQUISITION PRICE NONPUBLIC	ACQUISITION PRICE COMMENT
No	<p>In August 2017, SpringWorks entered into a license agreement with Pfizer, pursuant to which we acquired exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop and manufacture nirogacestat for the treatment, diagnosis and prevention of all diseases and commercialize nirogacestat for the treatment, diagnosis and prevention of all diseases other than Alzheimer’s disease, breast cancer and prostate cancer. Pursuant to the license agreement, SpringWorks is required to pay Pfizer up to an aggregate of \$232.5 million upon achievement of certain commercial milestone events, and will pay Pfizer tiered royalties on sales of nirogacestat at percentages ranging from the mid-single digits to the low 20s, that may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition.</p>

GENERAL COMMENTS

A large rectangular area for writing general comments, bounded by a solid black line on the top, right, and bottom edges, and a dashed black line on the left edge.